Co-Authors
This is a "connection" page, showing publications co-authored by VASSILIKI A PAPADIMITRAKOPOULOU and JEFFREY N MYERS.
Connection Strength
0.510
-
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 2011 Apr 01; 17(7):1815-27.
Score: 0.096
-
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
Score: 0.083
-
Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
Score: 0.067
-
Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med. 2023 03; 12(6):7508-7518.
Score: 0.055
-
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727.
Score: 0.055
-
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999 Oct; 125(10):1083-9.
Score: 0.044
-
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015 Nov; 8(11):1027-35.
Score: 0.033
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.023
-
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
Score: 0.018
-
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
Score: 0.013
-
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol. 2001 Jun 15; 19(12):3010-7.
Score: 0.012
-
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
Score: 0.011